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Abstract 
Cardiovascular diseases remain a major global health issue, with the development of 
atherosclerosis a major underlying cause. Our treatment of cardiovascular disease has 
improved greatly over the past 3 decades, but significant need still remains to reduce disease 
burden. Current priorities include reducing atherosclerosis advancement to clinically 
significant stages, and preventing plaque rupture or erosion. Inflammation and involvement 
of the adaptive immune system influences all these aspects and therefore is one focus for 
future therapeutic development. The atherosclerotic vascular wall is now recognised to be 
invaded from both sides (arterial lumen and adventitia), for better or worse, by the adaptive 
immune system. Atherosclerosis is also impacted at multiple stages by adaptive immune 
responses, overall providing multiple opportunities to target these responses to reduce disease 
progression. Protective influences that may be defective in diseased individuals include 
humoral responses to modified LDL and regulatory T cell responses. There are multiple 
strategies in development to boost these pathways in humans, including vaccine-based 
therapies. The impact of various existing adaptive immune targeting therapies, such as 
blocking critical costimulatory pathways or B cell depletion, on cardiovascular disease are 
beginning to emerge with important consequences for both autoimmune disease patients and 
the potential for wider use of such therapies. Entering the translation phase for adaptive 
immune targeting therapies is an exciting and promising prospect.  
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Introduction 
Cardiovascular diseases remain a major global health issue. A major underlying cause of 
myocardial infarction and stroke is atherosclerosis, the chronic inflammatory response to 
injury in the vascular wall of major arteries at specific sites of susceptibility (Lusis, 2000). 
Atherosclerotic plaque is initiated by accumulation and modification of low density 
lipoprotein (LDL) cholesterol below the endothelial cell layer. Subsequent progression, 
which may occur discontinuously over decades, include inflammatory activation, infiltration 
and proliferation of both immune cells and local vascular smooth muscle cells, and matrix 
deposition (Lichtman et al., 2013; Bentzon et al., 2014). The balance between accumulation 
of lipid-filled foam cells, lack of clearance of apoptotic or necrotic cells, deposition of 
extracellular matrix and immune cell polarization intrinsically determine the growth and 
stability of the plaque. Extrinsically, many factors impact on atherosclerosis, but perhaps 
none more prominently than circulating LDL levels. This is emphasised by the effectiveness 
of statins in reducing the risk of cardiovascular events (Collins et al., 2016). Plaque rupture, 
more specifically of the fibrous cap, is the most common cause of acute events. For example, 
rupture underlies 73% of fatal coronary thrombi (Falk et al., 2013), with plaque erosion the 
most common alternative event. In the era of cholesterol-lowering drugs (e.g. statins), there is 
a trend towards diminishing occurrence of plaque rupture (Libby and Pasterkamp, 2015). Our 
treatment of cardiovascular disease has improved greatly over the past 3 decades. For 
example, the UK has seen a 70% drop in age-adjusted cardiovascular mortality since 1979. 
However, over the same period, prevalence has remained stable (Bhatnagar et al., 2016). 
Current priorities include identifying at risk patients in more precise and timely ways, 
reducing atherosclerosis advancement to clinically significant stages, and preventing plaque 
rupture or erosion. Inflammation and recruitment of the adaptive immune system may be 
important in all of these aspects and is one focus for future therapeutic development. 
Adaptive immune cells, T cells and B cells, have a unique ability to create clonally distinct 
antigen receptors through somatic rearrangement of genomic DNA, and (in B cells) through 
further mutation. This creates an antigen receptor repertoire of near-global specificity; B cells 
recognise diverse epitopes within whole molecules, T cells recognise peptides presented 
within major histocompatibility complexes (MHC) on antigen presenting cells (APCs). The 
MHC Class I (for CD8+ T cells) and MHC Class II (for CD4+) are named human leukocyte 
antigens (HLA) in humans. Normally, multiple layers of tolerance mechanisms limit a 
significant involvement of T cells in non-infectious inflammation. These include deletion of 
autoreactive clones during thymic development, anergy through overstimulation, or 
dominance of regulatory T cells (Treg) that curtail initial T cell responses. T cell clones may 
overcome these mechanisms via defective negative selection, continued endurance of 
otherwise anergic T cells, or failed Treg control. T cell specificity, APC stimulatory capacity 
and cytokine milieu are key parameters dictating these changes. For example, CD4+ T cells 
are polarized to functional subtypes including Th1, Th2, Th17, follicular helper (Tfh) or 
Treg. B cells are also tamed by tolerance checkpoints; in addition the most potent, pro-
inflammatory responses are T cell-dependent, providing another level of control.  
The atherosclerotic vascular wall is invaded from both sides (arterial lumen and adventitia), 
for better or worse, by the adaptive immune system. We now understand a great deal about 
the impact of adaptive immune responses at different stages of cardiovascular disease, with 
both pathogenic and protective influences delineated. We are now in a phase of translating 
these findings to the clinic and trialling therapeutic strategies in patients. Inflammation may 
represent a significant proportion of the residual risk for cardiovascular disease remaining in 
patients on current therapies. If adaptive immune responses occur early on during disease 
development or before therapies are initiated, then despite reduction in risk factors (LDL 
cholesterol, innate cytokines), the memory compartment may endure and continue to produce 
pathogenic effectors. Strategies targeting adaptive immune components could therefore 
provide key future therapies to mitigate residual risk in patients. We will first discuss in turn 
analysis of human atherosclerotic patient samples, and functional studies in experimental 
models. We then summarize some of the therapeutic strategies targeting adaptive immunity 
currently being considered. 
Atherosclerosis and the Adaptive Immune System in Patients 
Local Evidence - T cells 
The most clinically relevant sites of atherosclerotic plaque development are the coronary and 
carotid arteries, with the aorta and its major branches also important sites in both humans and 
experimental models. Recent evidence significantly strengthened the association of adaptive 
immune infiltration with adverse outcomes or unstable status of plaques. T cells are found 
within coronary atherosclerotic plaques at multiple stages of disease progression (Boyle, 
1997; Liuzzo et al., 2000; Watanabe et al., 2007; Kortelainen and Porvari, 2014; Otsuka et 
al., 2015). Otsuka et al (2015) recently found CD3+ T cells in early lesions classified as 
pathological intimal thickening, but only once CD68+ cells (macrophages) were also present. 
T cells were then continuously present in later stages (fibroathermomas) of coronary arteries. 
Many studies have also detected T cells within carotid plaques (Kleindienst et al., 1993; 
Palma et al., 2006; de Boer et al., 2007; Chen et al., 2009; Erbel et al., 2011; Dietel et al., 
2013; Rohm et al., 2015). Plaques of otherwise similar status in older patients contain higher 
levels of infiltrating T cells (Najib et al., 2012). Both macrophages and T cells are present in 
higher proportions in the fibrous cap of ruptured plaques (Falk, 1983; Lendon et al., 1991; 
van der Wal et al., 1994; Boyle, 1997; Otsuka et al., 2015). Erbel et al (2011) recently 
showed that T cell infiltration was significantly associated with ischemia. In the aorta, an 
increased T cell response in both plaque and adventitia peaks in correlation with plaque 
instability, with reduced T cell infiltration in healed plaques (van Dijk et al., 2015). Increased 
infiltration of effector T helper cells rather than Treg cells is a hallmark of unstable compared 
to stable carotid artery plaques (Dietel et al., 2013; Rohm et al., 2015). Altogether, T cell 
responses are involved in both early plaque progression and late stage degradation of fibrous 
caps, but the links and similarities between these responses are still unclear. In addition to T 
cells themselves, the molecules able to locally activate T cells are abundantly expressed by 
APCs in atherosclerotic plaque, for example HLA (Jonasson et al., 1985; Xu et al., 1990) and 
costimulatory molecules (de Boer et al., 1997). In the adventitia of atherosclerotic vessels, 
adaptive immune cell infiltration is commonly detected, and can advance to formation of 
organized tertiary lymphoid organs (Boyle, 1997; Houtkamp et al., 2001; Clement et al., 
2014). CD8+ T cells are quite common in advanced human atheroma and are found both in 
plaque and adventitia (Zhou et al., 1996; van Dijk et al., 2015). Early studies suggested less 
involvement of CD8+ compared to CD4+ T cells (Zhou et al., 1996), but the potential 
importance of CD8+ T cells has now been revisited (see below). 
Initial studies more than 20 years ago demonstrated human plaque T cells respond to oxidized 
LDL (oxLDL)-derived peptides presented on HLA molecules (Stemme et al., 1995) and 
subsequently to heat shock protein (hsp)60 (Benagiano et al., 2005; Almanzar et al., 2012). 
In the study by Stemme et al (1995), isolation and stimulation of T cell clones from 
atherosclerotic plaques determined a significant proportion proliferated in response to oxLDL 
and were Th1 polarized, producing interferon (IFN)-γ. This seminal study established the 
paradigm that oxLDL represents a neo-self antigen responsible for activating and recruiting a 
T cell-driven autoimmune response against the artery wall. Benagiano et al., (2003) similarly 
found a predominance of CD4+ Th1 polarized clones. An alternative T cell antigen is hsp60, 
which is upregulated on inflamed endothelial cells. Hsp60 bears close similarity with 
bacterial hsp (GroEL), so T cells initially activated by bacterial antigens could also regulate 
atherosclerosis (Mosorin et al., 2000; Benagiano et al., 2005). 
Local Evidence – B cells and Antibodies 
B cells are very rare within atherosclerotic plaques themselves, but are more often found in 
adventitial inflammatory cell infiltrates (Boyle, 1997; van Dijk et al., 2015). PCR approaches 
have been successful in detecting the presence of B cells in the plaque and/or adventitia of 
coronary and carotid plaques (Burioni et al., 2009; Hamze et al., 2013). These studies 
showed the presence of class-switched, somatically mutated B cell receptor genes and the 
presence of limited but expanded clones. In addition, IgG and IgA expressing cells were most 
common in one study (Hamze et al., 2013). These studies confirm the presence of an active 
ongoing B cell humoral response in advanced stages of atherosclerosis. Interestingly, Hamze 
et al (2013) concluded that adventitial and plaque B cell clones were distinct and did not 
represent a directly linked response. How systemic responses that originate in spleen or 
draining lymph nodes relate in terms of antigen specificity and functional effects to local 
plaque and adventitial responses is currently unknown. 
Antibodies, however, abundantly bind within atherosclerotic plaques. The assumed major 
specificity of these antibodies is modified lipids, however many other autoantigens may be 
targeted (Merched et al., 2016). Modified lipid epitopes are certainly present, as exemplified 
by anti-phosphorylcholine (PC; clone E06) staining in plaques (van Dijk et al., 2012). As in 
other autoimmune diseases, a major target could also be extracellular matrix or nuclear 
antigens. High levels of anti-nuclear antibodies are not a prominent feature of coronary artery 
disease (CAD) patients unless autoimmunity is present. Nevertheless, one study associated 
enhanced circulating anti-nuclear antibodies in symptomatic compared to asymptomatic 
carotid artery stenosis patients (Döring et al., 2012). IgE is also found in human carotid 
atherosclerotic plaques in areas of high CD68 expression and TUNEL+ apoptotic cells (Wang 
et al., 2011). In terms of antibody effector pathways, the classical complement pathway 
(primarily initiated by immune complexes) appears to be active in human atherosclerotic 
plaques (Kimoto et al., 1996; Oksjoki et al., 2007). Antibodies also influence cellular 
functions via ligation of cell surface Fc receptors. There is a family of Fcγ receptors (I – IV) 
for IgG, FcεR (CD23) for IgE, FcµR (Toso) for IgM and the neonatal Fc receptor (FcRn), 
which is important in IgG recycling (Smith and Clatworthy, 2010). Macrophages within 
atherosclerotic plaques are influenced by IgG immune complexes via Fcγ receptors and 
vulnerable plaques exhibit enhanced levels of FcγR and downstream signalling molecules 
(Lennartz et al., 2011). FcγRIII (CD16) is an important marker of non-classical patrolling 
monocytes, compared to classical inflammatory monocytes that express high levels of the 
toll-like receptor 4 co-receptor CD14. Endothelial cells and vascular smooth muscle cells also 
express FcγR (Tanigaki et al., 2015). In summary, there is evidence for an adaptive immune 
cell response ongoing within atherosclerosis, as well as the presence of upstream activating 
and downstream effector pathways. The levels of these responses correlate closely with 
clinically relevant plaque status.  
Systemic, Genetic and Risk factor-related Evidence 
The analysis of circulating T cell subsets has also informed us about potential roles in 
cardiovascular disease (reviewed in Ammirati et al., 2015). As in atherosclerotic plaques, T 
cells reactive to oxLDL are present in the blood of cardiovascular disease patients 
(Frostegård et al., 1992). Various functional T cell subsets have been associated with CAD 
patients. Ammirati et al found a positive correlation between effector memory T cells and 
cardiovascular disease (Ammirati et al., 2012). In contrast, regulatory T cell levels are 
reduced in CAD patients (Mor et al., 2006; Ji et al., 2009; Wigren et al., 2012). A prominent 
feature of the cardiovascular patients’ T cell system is the expansion of an otherwise rare 
population of CD4+ CD28- T cells. This population increases with chronic inflammation, 
produces IFN-γ and acquires cytotoxic functionality not normally associated with CD4+ T 
cells (Dumitriu et al., 2012; Téo et al., 2013). One study found that CD4+ CD28- cells 
responded to hsp60 (Zal et al., 2004). Chronic low grade inflammation may promote re-
stimulation of these cells, leading to loss of CD28 (Bobryshev, 2010; Chistiakov et al., 2016), 
as well as resistance to apoptosis (Kovalcsik et al., 2014). Acute coronary syndrome (ACS) 
patients have a reduced T cell repertoire compared to healthy controls, suggesting accelerated 
ageing or systemic expansion of certain, perhaps autoreactive, clones (Klingenberg et al., 
2014). 
A large number of studies have correlated modified lipid-binding antibody levels to various 
aspects of cardiovascular disease, as reviewed in more detail elsewhere (Carbone et al., 
2013). A consistent finding is the inverse correlation of cardiovascular disease (CVD) with 
anti-oxidized lipid IgM antibodies (Karvonen et al., 2003). These ubiquitous and common 
antibodies may be important in limiting the accumulation of oxidized lipid debris and 
preventing foam cell formation. An alternative possibility could involve acting on PC and 
malondialdehyde (MDA)-positive bacteria. Low levels of anti-PC IgM can predict mortality 
(Carrero et al., 2009) whereas high levels are associated with slower atherosclerosis 
progression (Su et al., 2005; Ravandi et al., 2011). Single nucleotide polymorphisms (SNPs) 
close to genes encoding TNFSF13 (APRIL), a known plasma cell survival factor, and its 
receptor TNFRSF13B (TACI) were associated with IgM levels in humans (Osman et al., 
2012). IgG antibodies to the same epitopes have more inconsistent correlations. For example, 
Lehtimäki et al., (1999) found a significant positive association with atherosclerosis, whereas 
in a prospective observational study, Wilson et al., (2012) found no impact on risk. Another 
recent study demonstrated high levels of antibodies binding ApoB100 in LDL are associated 
with reduced CVD (Björkbacka et al., 2016). Khamis et al., (2016) recently found total IgG 
levels correlated with CVD and adjusting for total levels negated the correlation of oxLDL-
specific IgG. Increased serum IgE levels have been associated with enhanced risk of CAD, 
and in particular plaque stability (Kounis and Hahalis, 2016). In addition, IgE as well as 
eosinophil and mast cell responses occur as part of immune responses in acute coronary 
syndromes (Kritikou et al., 2016). 
A recent study used genomics data to determine that 2 B cell regulatory genes, TNFSF13B (B 
cell activating factor; BAFF) and SPIB, were the core regulatory factors in a module of genes 
co-regulated in non-CVD subjects but deregulated in CVD patients (Huan et al., 2013). 
Although neither BAFF nor SPIB are entirely B cell specific, this study supports the idea that 
significant changes in B cell responses are associated with CVD. A major function for 
interleukin (IL)5, and one of many functions of IL6, is to promote B cell humoral responses, 
and both IL5 and IL6R are candidate target genes of 2 genomic loci associated with CVD 
through GWAS analysis (Nikpay et al., 2015), as is the chromosome 6p21 region, which 
contains the Class I HLA locus (Davies et al., 2012). Soluble IL2Rα, a decoy receptor for 
lymphocyte growth factor IL2, associates with CVD even after adjustment for other risk 
factors; genetic polymorphisms at chromosome 10p15-14 influence the level of sIL2Rα, but 
do not directly link to increased incidence of CVD (Durda et al., 2015). The chemokine 
CXCL13 was recently shown to correlate closely with germinal center B cell responses in 
humans (Havenar-Daughton et al., 2016), although it does have innate immune functions as 
well. Higher CXCL13 levels were found in cardiovascular disease patients, particularly those 
with symptomatic status (Smedbakken et al., 2012). This systemic data supports the histology 
data showing adaptive immune responses correlating closely with plaque status (van Dijk et 
al., 2015; see above). 
Many central risk factors for cardiovascular disease and atherosclerosis may also elicit 
adaptive immune responses. The immune system declines with age (reviewed in Linterman, 
2014). However, a decrease in the strength of responses to infections or vaccinations is 
matched with a paradoxical increase in autoimmune propensity. The roles of adaptive 
immune responses in hypertension, obesity and type II diabetes have mainly been addressed 
in animal models and are considered briefly below.  
Atherosclerosis and the Adaptive Immune System in Experimental Models 
The functional importance of adaptive immunity in atherosclerosis is demonstrated by a 
plethora of in vivo studies in animal models, most extensively in the complementary mouse 
models of hypercholesterolemia, Apoe-/- and Ldlr-/- mice, but also in hypercholesteraemic 
rabbits. A limit to translating experimental findings into therapies is differences between the 
murine and human immune systems. Examples of significant differences include distinct 
functional properties of antibody isotypes and Fc receptor-dependent responses between mice 
and humans (Smith and Clatworthy, 2010) and the ability of mouse but not human thymus to 
maintain the naïve T cell pool (den Braber et al., 2012). A recent study suggested entirely 
different transcriptional profiles of mouse and human responses to a range of diseases (Seok 
et al., 2013), however this study was challenged soon after (Takao and Miyakawa, 2014). 
Accepting these caveats, major findings on the involvement of B cell and T cell responses in 
humans (as far as they are understood) are faithfully reproduced in mice. Several consistent 
findings allow us to assign important anti-atherogenic status to regulatory T cells and to 
natural IgM-producing B1 cells. Depletion of Tregs leads to increased atherosclerosis (Ait-
Oufella et al., 2006; Gotsman et al., 2006). Interference with conventional dendritic cells also 
leads to reduced Treg levels and increased atherosclerosis (Choi et al., 2011; Subramanian et 
al., 2013). As atherosclerosis progresses, local Treg levels are reduced in Ldlr-/- mice 
(Maganto-García et al., 2011). This could potentially relate to their conversion to Il17+ or 
IFN-γ producing Th1-like cells (Butcher et al., 2016). Regulatory T cells dampen immune 
responses in multiple ways and can both prevent responses from taking off as well as 
accelerating the resolution phase. Regulatory T cells are more sensitive than effector or naïve 
T cells to IL2. Once Treg recognise antigen, they can repress APC by removing 
costimulatory molecules (e.g. through cytotoxic T lymphocyte antigen-4 (CTLA4)) and by 
secreting IL10 and transforming growth factor-β.  
The protective role of B1 cells is supported by multiple studies in mouse models. The 
enhanced atherosclerosis in splenectomised mice is reversed by transfer of B1 but not B2 
cells (Kyaw et al., 2011). Both B1a (CD5+) and B1b (CD5-) cells are capable of producing 
atheroprotective IgM (Binder et al., 2003; Rosenfeld et al., 2015). Unlike IgG antibodies, 
IgM does not bind to pro-inflammatory Fc receptors on macrophages and neutrophils, 
although it can be associated with promoting antigen presentation to T Cells. The oxidized 
epitopes targeted by atheroprotective IgM are found on various circulating particles including 
oxLDL, Lipoprotein(a), apoptotic cells and microparticles, all of which may also accumulate 
within atherosclerotic plaques (Tsiantoulas et al., 2015). It remains to be determined whether 
IgM removal of all or only particular carriers of these epitopes is important for 
atheroprotection. An atheroprotective clonotype of anti-PC IgM, T15/E06, is encoded by the 
V1 heavy chain gene. Although IgM encoded by this gene is important for protection from 
Staphylococcus pneumoniae infection, atherosclerosis was not affected and overall IgM 
reactive with PC was not significantly affected (Centa et al., 2015). As the most prominent 
antagonist to these protective pathways, Th1 type CD4+ T cells promote atherosclerosis. 
Production of cytokines IFN-γ and IL12 are important mediators of this role (Davenport and 
Tipping, 2003; Buono et al., 2005). The IL1 family cytokine IL18 is also a strong signal for 
Th1 differentiation when in combination with IL12 or IL15 (Novick et al., 2013). In mice, 
IL18 promotes atherosclerosis (Mallat et al., 2001) and a recent paper showed it can act via 
both IL18 receptor and an alternative receptor, SLC12A3 (Wang et al., 2015). IFN-γ can 
activate macrophages towards a pro-inflammatory phenotype and also directly targets 
vascular cells. B cell production of granulocyte-monocyte-colony stimulating factor 
(Hilgendorf et al., 2014) and antigen presentation by plasmacytoid DCs (Sage et al., 2014) 
are upstream regulators of Th1-driven atherosclerosis.  
Other lymphocyte subsets have less well defined roles, with studies in mice showing 
opposing effects on atherosclerosis (Legein et al., 2013; Witztum and Lichtman, 2014; Taleb 
et al., 2015). This can be down to differences in experimental design and conditions between 
labs as well as to the multifunctional roles of theses subsets. For example, B2 cells have been 
ascribed both pathogenic and protective roles based on different experimental approaches. B2 
cell depletion leaving B1 cells intact leads to reduce atherosclerosis (Ait-Oufella et al., 2010; 
Kyaw et al., 2012; Sage et al., 2012), however adoptive transfer of purified B2 cells into B 
cell deficient (lacking both B1 and B2 cell) mice was either pro- or anti-atherogenic in 2 
different studies (Kyaw et al., 2010; Doran et al., 2012). Autoimmune disease models 
associated with B2 cell production of autoantibodies are generally associated with increased 
atherosclerosis (Gautier et al., 2007; Clement et al., 2014; Merched et al., 2016). Indirectly, 
knockout of pro-inflammatory IgG (Fcγ) receptors results in reduced atherosclerosis 
(Hernández-Vargas et al., 2006; Kelly et al., 2010), supporting a pathogenic role for 
autoantibodies. Although there is evidence of pathogenic influence, anti-oxLDL IgG is most 
likely protective in the same way as IgM of the same specificity. Treatment of atherosclerotic 
mice in a regression model (switched to chow from high-fat diet) with human monoclonal 
IgG1 to MDA-modified ApoB100 resulted in accelerated regression and 50% less 
atherosclerosis than the control group (Schiopu et al., 2007). Initial studies with mice lacking 
inhibitory FcγRIIb showed more atherosclerosis, however more recently the opposite effect 
was shown, with a mixed genetic background in the early studies a critical difference 
(Mendez-Fernandez et al., 2011; Harmon et al., 2014; Ng et al., 2015). Given the diverse 
subsets and response types of adaptive B2 cells, more models that can target specific 
functions or prevent antigen-specific responses are required to more accurately probe the 
potential roles for B2 cells. Several studies have suggested that CD8+ T cells, not commonly 
found in mouse atherosclerotic plaques, do not play a significant role in atherosclerosis (Zhou 
et al., 1996; Kolbus et al., 2012), however CD8+ T cells can promote atherosclerosis in some 
studies (Kyaw et al., 2013). A recent study demonstrated that in addition to their classical 
cytotoxic function, the lack of CD8+ T cells significantly modulated monocyte production in 
the bone marrow (Cochain et al., 2015). Given the recent genetic association of 
cardiovascular disease with the CD8+ T cell activating MHC Class I locus (Davies et al., 
2012), further study of the role of CD8+ T cells is certainly warranted. 
An adventitial adaptive immune response in the descending aorta of Apoe-/- mice can occur 
quite early during experimental models (Galkina et al., 2006; Koltsova et al., 2012), and in 
old Apoe-/- mice, these responses become organized into adventitial tertiary lymphoid organs 
(ATLO) (Srikakulapu et al., 2016). A recent study used smooth muscle cell-specific deletion 
of lymphotoxin β receptor to prevent ATLO formation and found that this exacerbated 
atherosclerosis (Hu et al., 2015). Microvessels are abundantly present in atherosclerotic 
plaque (Collett and Canfield, 2005), responding to plaque hypoxia (Marsch et al., 2014). 
Such microvascular networks provide the possibility for direct interaction of adventitial and 
plaque immunity. Adventitial responses can alternatively have systemic consequences for 
cardiovascular disease. T cell responses in perivascular adipose tissue are essential for the 
development of experimental hypertension (Itani et al., 2016), although human evidence of 
these links is sparse. In early atherosclerosis, dendritic cells scanning sites of atherosclerosis 
susceptibility were recently shown to exit back into the vessel lumen (intravasation) (Roufaiel 
et al., 2016), providing another potential route and suggesting systemic T cell recruitment. 
Beyond atherosclerosis models, T cell and B cell responses also play prominent roles in co-
morbidities for cardiovascular disease. Autoimmune driven arthritis and SLE have a clear 
adaptive immune component. Increasingly, models of type II diabetes reveal important 
potential roles for the adaptive immune system. Like in atherosclerosis, T cells that display an 
effector/memory phenotype, and are predominantly Th1-polarised, infiltrate obese adipose 
tissue and promote insulin resistance (reviewed in Majdoubi et al., 2016). B cell responses 
originating in adipose tissue may also be important in type II diabetes. For example, transfer 
of wildtype but not MHCII-/- B cells to B cell-deficient obese mice induced insulin resistance 
(Winer et al., 2011). 
Therapeutic Strategies Targeting the Adaptive Immune System 
Current therapies for cardiovascular disease designed to primarily target other disease 
processes may also act in part through actions on the adaptive immune system (reviewed in 
(Vré et al., 2011). The anti-inflammatory properties of cholesterol-lowering statins are well-
known (Jain and Ridker, 2005) including direct potential effects on adaptive immune 
responses. For example, simvastatin reduces MHCII expression (Kwak et al., 2000) . The 
complex relationship between lymphocytes and systemic lipid metabolism is receiving more 
attention (Chyu et al., 2014; Sorci-Thomas and Thomas, 2016). Angiotensin-converting 
enzyme inhibitors used to lower blood pressure may also directly target T cells, which 
express Angiotensin type 1 receptor and play an important role in Angiotensin II-induced 
vascular pathology (Guzik et al., 2007).  
Given the presence of both protective and pathogenic responses, therapeutic strategies 
designed against the adaptive immune system can be broadly divided into those attempting to 
boost protective pathways or those attempting to correct or inhibit pathogenic pathways. 
Strategies can also be global, by targeting costimulatory or cytokine signalling pathways, or 
antigen-specific. Costimulatory (or co-inhibitory) proteins form ligand-receptor pairs 
between interacting cell types and can dictate the outcomes for both cells and thus play a 
prominent role in guiding adaptive immune responses (den Haan et al., 2014). A prominent 
and well-studied costimulatory pairing is CD40-CD40 ligand, members of the TNF family. 
However, since this pathway has multiple impacts on atherosclerosis via important roles in 
innate immune cell or platelets as well as the adaptive immune response, we do not discuss 
this pathway further here (Gerdes et al., 2016; Jansen et al., 2016). Methods to isolate locally 
induced (i.e. ATLO) responses from systemic responses are currently lacking in the clinical 
setting, but could form the basis for future strategies. Below, we discuss antigen-independent 
strategies to boost Treg-mediated protection or attenuate pathogenic responses. Antigen-
specific immunization and tolerization strategies, targeting both T cells and B cells, are 
discussed finally. The targeted pathways of these strategies are illustrated in Figure 1. Most 
strategies outlined below could potentially attenuate both plaque progression and the risk of 
plaque rupture. Given the lack of widely used models of plaque rupture in mice, it is hard to 
assess impacts separately in experimental models. Immunization and tolerization strategies 
are the most likely strategy to be effective at earlier stages of disease.  
Regulatory T cell Enhancing Therapies 
Interference with CD80/86 – CD28 costimulation has shown to be an effective targeted 
immunosuppressive strategy, mimicking the effects of Tregs. Co-stimulation of CD28+ T 
cells via CD80/86 on APCs drives atherosclerosis in mice (Buono et al., 2004; Matsumoto et 
al., 2016). Biological therapies based on CTLA4 are approved for rheumatoid arthritis and 
kidney transplantation. In mice, translational studies using CTLA-Ig (Abatacept) have shown 
promise. Ewing et al showed decreased intimal hyperplasia and inflammation with abatacept 
(Ewing et al., 2013), whereas Ma et al showed effective inhibition of homocysteine-
accelerated atherosclerosis in Apoe-/- mice (Ma et al., 2013). IL2 triggers expansion and 
differentiation of both effector T cells and Treg. Treg have a significantly enhanced 
sensitivity to IL2 and this underlies the approach of treating patients with low dose IL2 to 
preferentially expand Treg with minimal impacts on effector T cells or other IL2R expressing 
cells (e.g. eosinophils) (Klatzmann and Abbas, 2015). Experimental studies characterized that 
low dose IL2, or IL2 in complex with an anti-IL2 antibody to enhance stability, preferentially 
expands Treg (reviewed in Pham et al., 2016). This therapeutic strategy holds promise in 
reducing many T cell mediated pathologies, or where an increased Treg response can limit 
inflammation-driven damage. In human clinical studies, low dose IL2 has been tested against 
type-1 diabetes, systemic lupus erythromatosus, and hepatitis C virus-induced vasculitis 
(Klatzmann and Abbas, 2015; Pham et al., 2016). One ‘side effect’ of this strategy is that IL2 
may also expand CD25+ innate lymphoid cells. The role of these cells in atherosclerosis is 
just beginning to be investigated (Engelbertsen et al., 2015). Furthermore, there is incomplete 
knowledge on how IL2 therapy impacts on the emerging plasticity of Treg (Butcher et al., 
2016).  
Costimulatory Pathway Targeting Therapies 
As an alternative to boosting Treg, therapies directly blocking effector T cell development or 
function could be developed to neutralise pathogenic T cell responses in atherosclerosis. Two 
prominent costimulatory pathways that inhibit or promote effector T cell responses are 
programmed cell death (PD-1) and Inducible T cell Costimulator (ICOS), respectively. 
Programmed cell death-1 (PD-1) and its ligands PD-L1 and PD-L2 are important in 
restraining pathogenic T cell responses. High PD-1 expression on T cells can also be 
associated with anergic or exhausted T cells in chronic inflammation in humans (McKinney 
et al., 2015) and may mark a pathogenic subset of T cells refractory to normal inhibitory 
signals. In murine atherosclerosis, PD-1 is associated with a protective role. Ldlr-/- mice 
lacking both PD-L1 and 2 develop enhanced systemic T cell activation, serum TNF and 
increased atherosclerosis (Gotsman et al., 2007). Pd1-/- mice also develop enhanced 
atherosclerosis (Bu et al., 2011; Cochain et al., 2014). In addition to systemic T cell 
activation, this was associated with increased apoptotic cell (both SMC and immune cells) 
accumulation within atherosclerotic plaques. Surprisingly, this result was not replicated in 
bone marrow chimeras with PD-L1/2 deficiency (Bu et al., 2011). Anti-PD1 antibody did not 
increase atherosclerotic size over a 3 week treatment but greatly increased T cell infiltration 
(Bu et al., 2011). Promoting PD-1 mediated immune restraint could therefore be beneficial in 
cardiovascular disease, in contrast to cancers where removing this inhibitory pathway enables 
anti-tumour T cell responses.  
ICOS and its ligand ICOSL are members of the B7 family and are very important in 
promoting T helper cell responses, including Tregs. Deletion of ICOS in bone marrow cells 
reduced Tregs and increased atherosclerosis in Ldlr-/- mice (Gotsman et al., 2006). ICOS-Fc 
treatment also led to increased atherosclerosis, although a significant level of anti-mouse 
ICOS antibodies was induced by the treatment (Afek et al., 2005). More recently, targeting 
ICOS-ICOSL was effective in reducing atherosclerosis in a mouse model of combined 
autoimmunity and atherosclerosis (Clement et al., 2014). Deficiency in CD8+ regulatory T 
cells led to a prominent expansion of CD4+ T cell activation, particularly B helper Tfh. 
ICOS-ICOSL interactions are crucial in B2 cell-Tfh interactions, and anti-ICOSL treatment 
reduced Tfh cell levels and atherosclerosis. The role of Tfh-mediated responses and effects of 
anti-ICOSL therapies in other models of atherosclerosis remain to be determined. A number 
of other costimulatory pathways have been associated with atherosclerosis in experimental 
models but progress towards the clinic is less advanced. For example, OX40 – OX40 ligand 
interactions promote T cell responses through stimulating both survival and expansion. In a 
regression model, where switching from western to chow diet (10 weeks of each) induces 
little change in plaque size but a very significant reduction in macrophages and expansion of 
collagen, anti-OX40 ligand induced plaque regression (Foks et al., 2013). Information on the 
impact of immunotherapies on cardiovascular parameters is constantly emerging, and this 
information is important in initiating novel strategies to directly counteract atherosclerosis 
progression. 
B Cell Depletion 
B cell depletion (BCD) therapy uses monoclonal antibodies against B cell-specific cell 
surface molecules such as CD20 or survival factors such as BAFF. BCD was developed 
against B cell derived cancers and is also now approved for use against autoimmune diseases. 
Although autoantibody production may also be modulated, impacts on effector/memory T 
cells may be the primary mode of action for B cell depletion (Lykken et al., 2014). Some 
human data on the impacts of B cell depletion on cardiovascular disease in autoimmune 
disease patients is beginning to emerge. Novikova et al. (2015)  detected a reduced cIMT in 
rituximab treated individuals while Provan et al. (2015)  found that after 12 months 
rituximab, pulse wave velocity, a measure of arterial stiffness, was reduced. A previous study 
(Raterman et al., 2013) found no impact on 6 months follow up. In atherosclerosis mouse 
models, primary studies showed reduced atherosclerosis when anti-CD20 treatment was 
administered prior to atherosclerotic development (Ait-Oufella et al., 2010; Kyaw et al., 
2010). It was also effective treating progression of pre-established atherosclerosis (Kyaw et 
al., 2010), with further mechanistic insight into how B cell-T cell interactions regulate 
atherosclerosis still required. In myocardial infarction (MI) models, B cell depletion was also 
protective but through a distinct mechanism. B cells producing CCL7 (MCP-3) are critical in 
recruiting destructive monocytes to the infarction site and thus B cell depletion may represent 
an acute strategy post-MI in reducing infarct inflammation (Zouggari et al., 2013). We 
believe that current broad targeting of B cells using depletion therapies may be more practical 
for the acute treatment of ischemic heart disease post-MI rather than for the long-term 
treatment of atherosclerosis, however more targeted strategies with similar mechanisms may 
well be suitable. Several anti-BAFF monoclonal antibodies, Belimumab, Tabalumab and 
Blisibimod, are in use in the clinic against autoimmune diseases and chronic lymphocytic 
leukaemia. In contrast to B cell depleting antibodies targeting B cell surface molecules 
(CD19, CD20, CD22), anti-BAFF therapies will also block other BAFF functions and so may 
have distinct modes of action. For example, BAFF may act directly on activated T cells 
(Scapini et al., 2010)  and the BAFF receptor TACI is reported to be expressed on 
macrophages in mice (Allman et al., 2015). BAFF may also have impacts on cholesterol 
metabolism and adipose tissue function (Jackson et al., 2016; Kim and Hyun, 2016). 
Antibodies against the BAFF receptor target more specifically the pathogenic B2 cell subset 
and are effective in mouse models (Kyaw et al., 2013b) but are not yet translated to humans. 
To date there has been no studies investigating cardiovascular parameters in patients treated 
with BAFF-targeting therapies. 
Immunization and Tolerization 
In most cases, immunization and tolerization against a particular antigen should result in 
opposite responses in the host. In the case of modified LDL, studies in rabbits and mice have 
shown that both immunization (injection of antigen with adjuvants), and tolerization (non-
adjuvant administration of peptides via oral or subcutaneous routes) can significantly reduce 
atherosclerosis (Palinski et al., 1995; Ameli et al., 1996; George et al., 1998). The target of 
tolerization is intentionally the regulatory T cell response, whereas immunization increases 
both innate and adaptive B cell responses, as well as regulatory T cell responses. The 
increased regulatory T cell response is proposed to be most active in reducing atherosclerosis, 
and may be the reason why both immunization and tolerization can protect from 
atherosclerotic development (Freigang et al., 1998), with increased Il5 that boosts innate B1 
cell responses also a functional protective pathway (Binder et al., 2004). Complexing the PC 
antigen into liposomes was also effective in reducing atherosclerosis (Hosseini et al., 2015). 
Immunization with human ApoB100 induced a Th2 response and an IgG1 antibody response 
to both human and mouse LDL, but did not affect atherosclerosis (Engelbertsen et al., 2014). 
An alternative target of such adaptive immune-targeted strategies is hsp60/65, a known target 
of pathogenic T cell responses in mice (Zhong et al., 2016). Others include β2-GPI (George 
et al., 2004) and modified fibronectin (Dunér et al., 2011). Interestingly, different peptides 
from hsp60 had opposite effects on T cell driven immune responses and on atherosclerosis 
(Grundtman et al., 2015), suggesting the peptide itself as well as the stimulatory profile of the 
APC and the environment, can modulate outcomes. The development of peptides promoting a 
tolerogenic (anti-atherogenic) response could form the basis for future targeted therapies for 
cardiovascular disease. Similarly, a study in mice demonstrated the protective effect of 
immunization with Streptococcus pneumonia polysaccharides, which contain PC epitopes 
(Binder et al., 2003). In humans, combined analysis of 8 observational studies suggest an 
association with pneumococcal polysaccharide vaccination and decreased risk of acute 
cardiovascular events in the older population (Ren et al., 2016). Recently, the AUSPICE trial 
was initiated to directly investigate the potential of this strategy (Ren et al., 2016). 
The same IgM-targeted epitopes of oxLDL (MDA, PC) are also present on apoptotic cells. 
Apoptotic cell treatment was successful in inducing a strong IgG anti-PC response as well as 
boosting anti-PC IgM levels, leading to reduced atherosclerosis (Grasset et al., 2015). This 
led to a decrease in circulating cholesterol through an as yet ill-defined mechanism. Thus, 
antibody responses could directly modulate atherosclerosis at the level of circulating 
cholesterol upstream of vessel accumulation and oxidation. However, previous studies of 
lymphocyte deficient mice (Sage et al., 2014), and mice in which regulatory T cells are 
depleted also show significant changes in circulating cholesterol levels (Klingenberg et al., 
2013). Impacts of modulation of dendritic cell levels, the archetypal T cell stimulating APC, 
on cholesterol have also complicated interpretation of those studies in understanding the 
importance of adaptive immune reactions in atherosclerosis (Gautier et al., 2009). 
Conversely, direct modulation of cholesterol in Apoe-/- mice can modulate CD4+ T cell 
responses (Chyu et al., 2014). Vaccination for atherosclerosis is an appealing concept and the 
integration of new knowledge both from ongoing human trials and from advanced 
interventions in mouse models will allow enhanced insight into the most effective mechanism 
to boost protective adaptive immunity. 
Conclusion 
Atherosclerosis is impacted at multiple stages by adaptive immune responses, providing 
multiple opportunities to target these responses to reduce disease progression. Protective 
influences defective in diseased individuals include humoral responses to modified LDL and 
regulatory T cell responses. There are diverse strategies in development to boost these 
pathways in humans. Alternative strategies to neutralise pro-inflammatory adaptive responses 
include blocking critical costimulatory pathways or other indirect anti-inflammatory 
treatments such as B cell depletion. Entering the translation phase is an exciting and 
promising prospect but issues include showing efficacy above existing therapies, such as 
statins, which may also have direct anti-inflammatory effects on top of lipid-lowering. In 
addition, our knowledge of the network interactions within the immune system, and crosstalk 
with metabolic homeostasis must improve to develop accurately targeted treatments. 
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Figure Legends 
Figure 1. Potential Therapeutic Strategies Targeting Adaptive Immunity in Atherosclerosis  
Adaptive immune responses initiate in lymphoid organs (spleen, lymph nodes and in atherosclerosis 
in inflamed adventitia). Cell-cell interactions between dendritic cells, naïve T cells and B2 cells, 
dependent on costimulatory molecules and cytokines, result in atherogenic responses such as effector 
T cells and pathogenic autoantibodies from B2 cells but also protective responses such as regulatory T 
cells (Treg). B1 cells (and B2 cells) are stimulated by antigen and cytokines such as IL5 to produce 
atheroprotective anti-oxidation specific epitope (OSE) antibodies. Atherosclerosis is driven by 
macrophage foam cell formation leading to necrotic core formation. Rupture of the fibrous cap of 
smooth muscle cells and collagen matrix is a key therapeutic target. Pathogenic T cells (e.g. Th1), 
antagonised by Treg, promote inflammation and cell death of endothelial cells, smooth muscle cells 
and macrophages. Pathogenic autoantibodies, that bind plaque cells or extracellular matrix, may also 
promote inflammatory activation of vascular and immune cells. Protective antibodies neutralize and 
promote uptake of apoptotic/necrotic cells, modified lipids and microparticles. The point of 
intervention for potential therapeutic strategies (red boxes) are indicated. 
  
 
